Systemic treatment with drugs is administered to prolong survival and palliate symptoms in Stage IV breast cancer patients who have distant metastases at diagnosis. Surgical procedures for the primary tumor are not actively recommended in guidelines due to lack of evidence indicating prognostic benefit. Recently, several retrospective studies have shown primary tumor resection to prolong overall survival in patients with Stage IV breast cancer. Prospective randomized trials began enrolling patients to examine this possibility and two have already reported results. However, the results of these two trials were discordant. The first trial, conducted in India, reported negative effects of primary tumor resection after primary systemic therapy. A Turkish trial then obtained a positive effect of surgery as primary treatment. Several questions regarding the effects, timing, methods and eligibility for primary surgery have yet to be answered. Robust evidence, which is anticipated from other ongoing trials examining surgery for metastatic breast cancer, is eagerly awaited.
Introduction
About 90 000 women were newly diagnosed with breast cancer, and 3% had Stage IV, in Japan in 2015. Stage IV breast cancer has already metastasized to distant regions when diagnosed. Cure is not possible for these patients, because the cancer cells have spread throughout the body. The aim of treatment is to 'prolong survival and palliate symptoms'. Hormone therapy, chemotherapy and molecular targeted agents are administered, according to their predicted of efficacies, as systemic therapies. Recently, appropriate use of new drugs, becoming available annually, has allowed long-term control of symptoms due to metastases and has prolonged the lives of patients. In addition, there have been remarkable advances in diagnostic imaging examinations. We can now detect extremely small metastases that could not previously be visualized by traditional imaging modalities (1) . Stage IV breast cancer with small metastases is referred to as 'minimal Stage IV disease (2)' and these patients may have a better prognosis than those with standard Stage IV breast cancer. Moreover, the concept of 'oligometastasis' is currently being debated (3) . According to this concept, even distant metastases, depending on their location and number, can potentially be cured with an aggressive treatment strategy that includes surgery.
Resection of a primary tumor is not actively recommended by guidelines due to lack of high-level evidence indicating prognostic benefit. While clinical experience indicates that resection can be useful for alleviating chest symptoms, such as bleeding and ulceration as well as pain due to invasion of the chest wall, no studies or prospective trials have determined whether or not earlier surgery achieves better local control and/or prolongs survival. Several recent retrospective studies have demonstrated that resection increases survival time (4) (5) (6) (7) (8) (9) (10) . The surgical procedures for breast cancer can be safely performed with minimal invasiveness. Administration of systemic drugs to patients with Stage IV breast cancer does have a few adverse effects, but these are outweighed by the survival effects. The efficacy of and indications for surgery, as part of an optimal treatment strategy for Stage IV breast cancer tailored to individual situations, require evaluation. Defining the role of surgery for Stage IV breast cancer may substantially alter future treatment strategies.
Surgery for cancer patients with metastatic disease
According to the seed and soil theory developed by Paget (11) , distant metastasis is a systemic disease. Cancer cells have already spread throughout the systemic circulation by the time distant metastases are detected. Thus, local therapies do not affect overall survival. Moreover, Fisher et al. raised the possibility that primary tumor resection may promote the progression of distant metastases (12) . This might be attributable to resection of the primary tumor triggering surgical dissemination with increased adhesion of circulating tumor cells to the vascular endothelium of target organs (13), surgery-induced immunosuppression (14) , surgery-induced angiogenic switch or the inflammatory cascade.
However, there are several other theories possibly explaining the basic rationale for resection of the primary tumor increasing the survival time of patients with Stage IV breast cancer. A reduction in circulating tumor cells according to primary tumor resection reportedly correlates with prognosis (15) . Moreover cancer stem cells, found mainly in the primary tumor, tend to be resistant to systemic drugs (16) . Resection of the primary tumor can reduce the tumor volume, including that of cancer stem cells, thereby reactivating autoimmunity and increasing the efficacy of systemic therapies (17) . In addition, the concept of 'cell seeding' highlights the important features of cancer cells comprising the primary tumor. This concept suggests that cancer cells released into the blood from the primary tumor return to be activated in the primary tumor (18) . Both of these hypothetical mechanisms are based on the results of basic experiments. It is very important to demonstrate similar results clinically by conducting prospective studies.
A prospective clinical study demonstrated that resection of the primary tumor is useful when kidney cancer is in Stage IV (19) . According to that study, resection of the primary tumor is a theoretical basis for the effectiveness of surgery. The REGATTA trials evaluated the efficacy of gastrectomy for Stage IV gastric cancer before chemotherapy. However, gastrectomy followed by chemotherapy yielded no survival benefit as compared with chemotherapy alone in advanced gastric cancer patients with a single non-curable factor (20) . The authors suggested one of the reasons to be reduced compliance with chemotherapy after surgery due to adverse events like weight loss. These results underscore the importance of both surgery and systemic therapy. Patients with Stage IV renal cancer can expect relatively long survival with systemic therapy, while the prognosis of Stage IV gastric cancer patients is worse and there are fewer effective systemic therapies than for other types of cancer. To maximize the efficacy of operative treatment, not only surgery but also effective systemic therapy is necessary.
The results of retrospective studies for Stage IV breast cancer
A number of recent retrospective studies have demonstrated the prognostic benefits of primary tumor resection for Stage IV breast cancer. The results of many of these studies suggested that surgery prolonged survival time. Moreover, several comprehensive reviews have described significant differences in survival time (Hazard Ratio of~0.6) (4,5). According to subgroup analyses (21) , 'complete excision of the primary tumor', 'metastasis only to bone and/or soft tissue', 'few metastases' and 'being younger' were factors indicating a patient to be an appropriate candidate for surgery (6, 7) . There are some studies showing differences in the benefits of surgery among different tumor subtypes (22, 23) . On the other hand, another study showed a more satisfactory outcome for asymptomatic than for symptomatic patients, whether or not treatment was administered and regardless of the type of treatment (24) . This result raised the possibility that local control itself may act beneficially on prognosis, irrespective of whether treatment is classified as surgery or radiation. However, all of the findings cited were based on retrospective analyses, such that numerous biases are possible. Patients undergoing surgery might be in sufficiently good condition for surgery, while those not receiving surgical treatment might be unable to undergo an operation due to their poor overall conditions. In addition, details regarding efficacy and the disease control rate for systemic therapy are lacking. There is no clear answer as to whether surgery should be performed during initial treatment or whether it should be a final option after essentially all potentially effective medications have been tried. Moreover, adverse effects of surgery in such patients are largely unknown. The major adverse events associated with surgery for breast cancer patients are seroma, surgical site infection and thrombosis. These events are only rarely critical but they can impact the systemic treatment schedule. Data from prospective studies are needed to resolve these issues.
Prospective trial evaluating primary tumor resection for Stage IV breast cancer
Five prospective randomized trials have analyzed the efficacy of primary tumor resection for Stage IV breast cancer (25) ( Table 1) (26) . Two have reported final results and the others are still currently enrolling patients or following up. The first results were those of an Indian trial (27) . The efficacy of locoregional treatment for Stage IV breast cancer patients receiving systemic therapy was evaluated. The authors reported that locoregional treatment of the primary tumor did not affect overall survival. In addition, the distant disease free survival of patients receiving surgery was significantly poorer than that of patients not undergoing surgery. The results from a Turkish trial, conversely, suggested a positive effect of surgery (28) . The authors reported that primary tumor resection as the initial treatment for newly diagnosed Stage IV breast cancer significantly prolonged overall survival. Estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative, being young (<55 years of age) and solitary bone metastasis were factors predicting the benefit of surgery. One of the most important reasons for the difference in results between these two trials is how systemic therapies were used. In the Indian trial, systemic therapies were not selected according to breast cancer subtypes nor was systemic chemotherapy continued after randomization. Notably, trastuzumab, which is a molecular targeting therapy, was not used for patients with HER2 positive tumors and very few patients with ER positive tumors received hormone administration as primary systemic therapy. In the Turkish trial, on the other hand, recently developed systemic drugs were used. Thus, the median survival time in the Indian trial (~20 months) was shorter than that in the Turkish trial (46 months in the surgery group and 37 months in non-surgery group). Moreover, there was uncertainty regarding the detection of metastases. Only bone scintigraphy was used to diagnose bone metastases. Therefore, the Indian trial failed to enroll even a small number of patients with oligometastases, and most of their patients had highly advanced disease with a very large tumor burden. On the other hand,~10% of patients randomized to the non-surgery group ultimately underwent surgery to achieve control of local symptoms after protocol treatment in both trials. According to these results, there is a possibility that primary tumor resection provides survival benefits for some Stage IV breast cancer patients and that~10% of Stage IV patients require primary tumor resection for control of local disease symptoms. However, this approach does not constitute routine therapy for all Stage IV breast cancer cases. The details of eligibility for surgery need to be clearly established employing data from other ongoing trials.
The Breast Cancer Study Group of the Japan Clinical Oncology Group (1017) and Eastern Clinical Oncology Group (2108) began enrolling patients for a Phase 3 trial in June 2011 (20) . In these trials, patients received the most up-to-date standard systemic therapy available before and after randomization and also the most advanced form of imaging examination available before treatment.
The other two trials, currently enrolling patients in Thailand and Austria, will evaluate the efficacy of surgery as initial therapy, employing an approach similar to that in the Turkish trial. Several questions regarding the effects, timing, methods and eligibility for primary tumor resection remain to be answered. It is anticipated that the aforementioned trials will resolve current controversies and provide many eagerly awaited answers.
Conclusion
At present, whether primary tumor resection for Stage IV breast cancer provides any clinical benefit is unclear. According to the results obtained in two trials, routine surgery for all Stage IV breast cancer patients is not warranted, though some do obtain benefits from surgery and it is necessary to establish reliable means of identifying such patients (29) . However, as yet, robust and definitive evidence supporting the use of surgery is lacking. Breast cancer is not a single disease and there are subtypes which must be considered when devising individual treatment strategies. We can achieve disease control by appropriately using systemic chemotherapeutic agents, based on analyses of cancer biology (30) . However, the costs of new drugs constitute a major challenge in cancer treatment. Our aim should be to devise the most effective treatment strategies for individual cancer patients, employing drugs, surgery and radiation, alone or in combination. The treatment goals for Stage IV breast cancer are to prolong the patient's survival time and to control symptoms. Detailed examinations of the results of ongoing clinical trials are anticipated to provide the high-level evidence necessary to optimize the treatments we can offer our patients. An effective strategy for treating Stage IV breast cancer must incorporate both symptom amelioration and survival prolongation, while remaining mindful of the significance of surgery. Table 1 . 
